HOME >> MEDICINE >> NEWS
Use of estrogen by postmenopausal women does not increase risk of breast cancer

CHICAGO Postmenopausal women treated with estrogen therapy for seven years did not experience an increased risk of breast cancer, according to a study in the April 12 issue of JAMA.

The Women's Health Initiative (WHI) Estrogen-Alone trial, which randomized women with prior hysterectomy to conjugated equine estrogens (CEE) or placebo, was stopped earlier than planned because of increased stroke incidence and no reduction in risk of coronary heart disease. In contrast to substantial epidemiological evidence associating exogenous (originating externally) estrogens with increased breast cancer incidence, preliminary analyses found fewer breast cancers in women in the CEE group, prompting a detailed updated analysis of breast cancer incidence and mammographic reports.

Marcia L. Stefanick, Ph.D., of Stanford University, Stanford, Calif., and colleagues with the WHI study, analyzed the data from the CEE-alone group of the WHI study to determine the effects of CEE on breast cancers and mammographic findings. The study included 10,739 postmenopausal women aged 50 to 79 years with prior hysterectomy who were randomized to CEE or placebo at 40 U.S. clinical centers from 1993 through 1998. Mammography screenings and clinical breast examinations were performed at baseline and annually. All breast cancers diagnosed through February 29, 2004, are included. Participants received a dose of 0.625 mg/d of CEE or an identical-appearing placebo.

In an analyses of all events (n = 237 cases) occurring prior to intervention termination, after an average follow-up of 7.1 years, nonsignificant reductions were observed for invasive breast cancer (20 percent lower rate) and for total breast cancer (18 percent lower rate) in women randomized to CEE, when compared to the placebo group. The annualized rates were 0.28 (104 cases in the CEE group) and 0.34 (133 cases in the placebo group). In further analyses, fewer breast cancers with localized disease were diagnosed
'"/>

Contact: Susan Ipaktchian
650-725-5375
JAMA and Archives Journals
11-Apr-2006


Page: 1 2

Related medicine news :

1. COX inhibitors may weaken protective qualities of estrogen hormone therapy
2. Study describes action of estrogen in protecting bone
3. New path from estrogen to survival in breast cancer cells described
4. High estrogen levels associated with dementia in older men
5. Ultra low-dose estrogen shown safe for post-menopausal women
6. Gabapentin cools hot flashes as well as estrogen
7. Study uncovers significant functional differences of novel estrogen receptor
8. Early estrogen exposure leads to later prostate cancer risk
9. Long-term estrogen therapy linked to breast cancer risk
10. Low estrogen levels in men linked to increased risk for hip fracture
11. Benefit of chemotherapy in breast cancer depends on estrogen-receptor status

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert standing desk ... and advantages built into the home office sit stand solution are bold colors, ... to gain the benefits embedded in the TaskMate Go are available 24/7 through ...
(Date:2/24/2017)... ... 2017 , ... Dr. Ronald E. Hawkins, vice president for ... Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of ... Bell comes to Liberty from the Ohio University Heritage College of Osteopathic Medicine ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal ... Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, ... his attempts to overcome them. , Schanssema, initially unsure of the career path he ...
(Date:2/24/2017)... ... ... Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that he will ... the Management Committee when IFN was originally formed in 2002 where he was ultimately ... of the business plan. He became the first paid employee of IFN in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Report analyzes the worldwide markets for Endodontic ... for the US, Canada , ... Asia-Pacific , Latin America , and ... the period 2015 through 2022. Also, a six-year historic analysis ... derived from primary and secondary research. Company profiles are primarily ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017  This ... US$ Thousand by the following Products: ... analyzed in the report include Pharmaceuticals, and Agrochemicals. The ... Japan , Europe , ... provided for the period 2015 through 2022. Also, a ...
(Date:2/24/2017)... Wyoming , Feb. 24, 2017  Xynomic Pharmaceuticals, ... today announced that it has acquired exclusive worldwide ... potentially best-in-class innovative HDAC inhibitor targeting hematological and ... of 14 Phase 1 and 2 clinical trials ... Asia have already been completed, demonstrating ...
Breaking Medicine Technology:
Cached News: